These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 12213538)

  • 1. Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited.
    Järbe TU; Andrzejewski ME; DiPatrizio NV
    Pharmacol Biochem Behav; 2002 Nov; 73(4):911-9. PubMed ID: 12213538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats.
    Järbe TU; DiPatrizio NV; Li C; Makriyannis A
    Pharmacol Biochem Behav; 2003 Jul; 75(4):809-21. PubMed ID: 12957223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
    Janoyan JJ; Crim JL; Darmani NA
    Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats.
    Järbe TU; DiPatrizio NV; Li C; Makriyannis A
    Behav Pharmacol; 2007 Nov; 18(7):673-80. PubMed ID: 17912052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (-)-Adamantyl-delta8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats.
    Järbe TU; DiPatrizio NV; Lu D; Makriyannis A
    Behav Pharmacol; 2004 Nov; 15(7):517-21. PubMed ID: 15472574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats.
    Järbe TU; DiPatrizio NV
    Behav Pharmacol; 2005 Sep; 16(5-6):373-80. PubMed ID: 16148441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats.
    Järbe TU; Liu Q; Makriyannis A
    Psychopharmacology (Berl); 2006 Jan; 184(1):36-45. PubMed ID: 16307294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.
    Järbe TU; LeMay BJ; Olszewska T; Vemuri VK; Wood JT; Makriyannis A
    Pharmacol Biochem Behav; 2008 Nov; 91(1):84-90. PubMed ID: 18640150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
    Darmani NA
    Pharmacol Biochem Behav; 2001; 69(1-2):239-49. PubMed ID: 11420092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats.
    Mansbach RS; Rovetti CC; Winston EN; Lowe JA
    Psychopharmacology (Berl); 1996 Apr; 124(4):315-22. PubMed ID: 8739546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats.
    Manzanares J; Corchero J; Fuentes JA
    Brain Res; 1999 Aug; 839(1):173-9. PubMed ID: 10482810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats.
    Järbe TU; Ross T; DiPatrizio NV; Pandarinathan L; Makriyannis A
    Pharmacol Biochem Behav; 2006 Sep; 85(1):243-52. PubMed ID: 16996123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide.
    Järbe TU; Lamb RJ; Lin S; Makriyannis A
    Psychopharmacology (Berl); 2001 Aug; 156(4):369-80. PubMed ID: 11498713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
    Darmani NA
    Neuropsychopharmacology; 2001 Feb; 24(2):198-203. PubMed ID: 11120402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats.
    Solinas M; Panlilio LV; Antoniou K; Pappas LA; Goldberg SR
    J Pharmacol Exp Ther; 2003 Jul; 306(1):93-102. PubMed ID: 12660305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist.
    Järbe TU; Harris MY; Li C; Liu Q; Makriyannis A
    Psychopharmacology (Berl); 2004 Dec; 177(1-2):35-45. PubMed ID: 15167981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
    Järbe TU; Lamb RJ; Liu Q; Makriyannis A
    Eur J Pharmacol; 2003 Apr; 466(1-2):121-7. PubMed ID: 12679148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine.
    Williams CM; Kirkham TC
    Pharmacol Biochem Behav; 2002; 71(1-2):333-40. PubMed ID: 11812541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
    Craft RM; Wakley AA; Tsutsui KT; Laggart JD
    J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats.
    Costa B; Vailati S; Colleoni M
    Behav Pharmacol; 1999 May; 10(3):327-31. PubMed ID: 10780247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.